Gilead offers Egypt new hepatitis C drug at 99 percent discount - (Yahoo!News via NewsPoints Desk)

  • Gilead Sciences disclosed a plan to offer the hepatitis C therapy Sovaldi at a price of $900 for 12 weeks of treatment in Egypt, representing a 99-percent discount to its price in the US, as reported Yahoo!News Friday.
  • Gilead has faced criticism concerning the $84 000 price of the drug in the US, with US lawmakers questioning the treatment's price after health insurers said they would ask state health officials to help cover the drug's cost.
  • Gilead noted that it was "pleased to have finalised an agreement" for launching Sovaldi in Egypt, which has the world's highest prevalence of hepatitis C.
  • According to a report, Egyptian health minister Adel El-Adawi remarked that the country reached an agreement with Gilead for the government to purchase a one-month supply of the therapy for $300.
  • The health minister added that the offer would apply to the use of the drug in government clinics, with access programmes starting in the second half of 2014 after the completion of registration procedures in the country.
  • Analysts project that Sovaldi will amass global revenue of $9.1 billion by 2017.

To read more NewsPoints articles, click here.